Human Enterovirus 71 Protein Displayed on the Surface of Saccharomyces cerevisiae as an Oral Vaccine.
Human enterovirus 71 (EV-A71), a major agent of hand, foot, and mouth disease, has become an important public health issue in recent years. No effective antiviral or vaccines against EV-A71 infection are currently available. EV-A71 infection intrudes bodies through the gastric mucosal surface and it is necessary to enhance mucosal immune response to protect children from these pathogens. Recently, the majority of EV-A71 vaccine candidates have been developed for parenteral immunization. However, parenteral vaccine candidates often induce poor mucosal responses. On the other hand, oral vaccines could induce effective mucosal and systemic immunity, and could be easily and safely administered. Thus, proper oral vaccines have attached more interest compared with parenteral vaccine. In this study, the major immunogenic capsid protein of EV-A71 was displayed on the surface of Saccharomyces cerevisiae. Oral immunization of mice with surface-displayed VP1 S. cerevisiae induced systemic humoral and mucosal immune responses, including virus-neutralizing titers, VP1-specific antibody, and the induction of Th1 immune responses in the spleen. Furthermore, oral immunization of mother mice with surface-displayed VP1 S. cerevisiae conferred protection to neonatal mice against the lethal EV-A71 infection. Furthermore, we observed that multiple boost immunization as well as higher immunization dosage could induce higher EV-A71-specific immune response. Our results demonstrated that surface-displayed VP1 S. cerevisiae could be used as potential oral vaccine against EV-A71 infection.
1 School of Life Sciences, Anhui University , Hefei, China .|2 Southern China United Vaccine Institute , Guangzhou, China .
Congdang
C
Zhang
2 Southern China United Vaccine Institute , Guangzhou, China .
Yi
Y
Wang
2 Southern China United Vaccine Institute , Guangzhou, China .
Shuzhi
S
Ma
3 State Key Laboratory of Respiratory Disease, Sino-French Hoffmann Institute, Guangzhou Medical University , Guangzhou, China .
Leike
L
Li
2 Southern China United Vaccine Institute , Guangzhou, China .
Liyun
L
Chen
4 The State Key Laboratory of Virology, Wuhan Institute of Virology , Chinese Academy of Sciences, Wuhan, Hubei, China .
Huimin
H
Yan
2 Southern China United Vaccine Institute , Guangzhou, China .|3 State Key Laboratory of Respiratory Disease, Sino-French Hoffmann Institute, Guangzhou Medical University , Guangzhou, China .
Tao
T
Peng
D000284:Administration, Oral; D000818:Animals; D000831:Animals, Newborn; D057134:Antibodies, Neutralizing / Q000096:biosynthesis*; D000914:Antibodies, Viral / Q000096:biosynthesis*; D036022:Capsid Proteins / Q000235:genetics / Q000276:immunology*; D029821:Enterovirus A, Human / Q000254:growth & development / Q000276:immunology; D004769:Enterovirus Infections / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D005260:Female; D006801:Humans; D056724:Immunity, Humoral; D007112:Immunity, Maternally-Acquired; D018928:Immunity, Mucosal; D007115:Immunization Schedule; D000071497:Immunogenicity, Vaccine; D008565:Membrane Proteins / Q000235:genetics / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D012441:Saccharomyces cerevisiae / Q000235:genetics / Q000276:immunology*; D018417:Th1 Cells / Q000276:immunology / Q000821:virology; D019076:Transgenes; D014611:Vaccination; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D036022:Capsid Proteins; D008565:Membrane Proteins; D014765:Viral Vaccines